Related Links

Selected Publications from 2019


Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial
Bhattacharya IS, Haviland JS, Kirby AM, Kirwan CC, Hopwood P, Yarnold JR, Bliss JM, Coles CE; IMPORT Trialists
Journal of Clinical Oncology   2019  37:4  305-371
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA;.PERSEPHONE Steering Committee and Trial Investigators.
Lancet  2019  393(10191)  2599-2612
Microenvironmental IL1ß promotes metastatic colonisation of breast cancer cells in the bone via activation of Wnt
Eyre R, Alférez DG, Santiago-Gómez A, Spence K, McConnell JC, Hart C, Simões BM, Lefley D, Tulotta C, Storer J, Gurney A, Clarke N, Brown MD, Howell SJ, Sims AH, Farnie G, Ottewell PD and Clarke RB
Nature Communications  2019  10(1)  5016
Long term results of the International Breast cancer Intervention Study II (IBIS-II) using Anastrozole for Breast Cancer Prevention
Jack Cuzick PhD, Ivana Sestak PhD, John F Forbes MD, Mitch Dowsett PhD3, Gareth Evans MD, Simon Cawthorn MD, Robert E Mansel MD, Sibylle Loibl MD, Bernardo Bonanni MD , Anthony Howell MD on behalf of the IBIS-II investigators
Lancet  2019  395(10218)  117-122
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
Rothwell DG, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E, Smith N, Villa S, Dransfield J, Clipson A, White D, Nessa K, Ferdous S, Howell M, Gupta A, Kilerci B, Mohan S, Frese K, Gulati S, Miller C, Jordan A, Eaton H, Hickson N, O'Brien C, Graham D, Kelly C, Aruketty S, Metcalf R, Chiramel J, Tinsley N, Vickers AJ, Kurup R, Frost H, Stevenson J, Southam S, Landers D, Wallace A, Marais R, Hughes AM, Brady G, Dive C, Krebs. MG.
Nature Medicine  2019  25(5)  738-743


Date:  29 October 202009:00
Speaker:  Professor Geoff Lindeman
From:  Walter and Eliza Hall Institute of Medical Research (WEHI), Melbourne
Title:  Targeting pro-survival proteins to enhance tumour response in breast cancer
Host:  Rob Clarke
Date:  17 November 202015:00
Speaker:  Dr Jeffrey Rosen
From:  Baylor College of Medicine, Houston
Title:  Leveraging Preclinical Models of Breast Cancer
Host:  Rob Clarke